IPSEN (OTCMKTS:IPSEY) Stock Crosses Above 200-Day Moving Average – Should You Sell?

IPSEN (OTCMKTS:IPSEY) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $33.27 and traded as high as $35.19. IPSEN shares last traded at $35.19, with a volume of 973 shares traded.

Analyst Ratings Changes

A number of brokerages have recently commented on IPSEY. BNP Paribas downgraded shares of IPSEN to an “underperform” rating in a research note on Wednesday, November 26th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IPSEN in a report on Monday, November 3rd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, IPSEN presently has a consensus rating of “Hold”.

IPSEN Stock Performance

The business’s 50 day moving average price is $35.57 and its 200-day moving average price is $33.30.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).